MPO-DNA
otherCirculating NET component serving as marker of pathogenic neutrophil activation and thrombo-inflammatory burden post-MI.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleNET burden marker reflecting myeloperoxidase-containing neutrophil extracellular traps.
Also acts inPlatelet activation
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I56
C — non-Type-I55
A — assay feasibility45
E — evidence strength24
T1DI (composite)6
Specificity differential (R−C)+1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Method depends on analyte chemistry
Reagent / substrate
Analyte-specific
Platform
Variable
Turnaround · availability
Research · Research
Literature evidence(2)
- Silent Myocardial Infarction Revisited: Immuno-metabolic Mechanisms, Multimodal Biomarkers, and Translational Diagnostics.Journal of cardiovascular translational research · 2026 · PMID 41784746 · doi
- Linking Neutrophil Extracellular Traps and Platelet Activation: A Composite Biomarker Score for Predicting Outcomes after Acute Myocardial Infarction.Thrombosis and haemostasis · 2021 · PMID 33984869 · doi